Denis M. Collins

1.6k total citations
53 papers, 1.2k citations indexed

About

Denis M. Collins is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Denis M. Collins has authored 53 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 18 papers in Radiology, Nuclear Medicine and Imaging and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Denis M. Collins's work include HER2/EGFR in Cancer Research (27 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Denis M. Collins is often cited by papers focused on HER2/EGFR in Cancer Research (27 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Denis M. Collins collaborates with scholars based in Ireland, United Kingdom and United States. Denis M. Collins's co-authors include John Crown, Norma O’Donovan, Birgit Bossenmaier, Alex J. Eustace, Gwendlyn Kollmorgen, Gerhard Niederfellner, Michael J. Duffy, Finbarr O’Sullivan, Neil T. Conlon and Patricia M. McGowan and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Denis M. Collins

51 papers receiving 1.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Denis M. Collins 671 479 282 210 156 53 1.2k
James Russell 396 0.6× 623 1.3× 230 0.8× 213 1.0× 483 3.1× 45 1.4k
Antje‐Christine Walz 349 0.5× 402 0.8× 166 0.6× 89 0.4× 84 0.5× 34 892
Bea Pauwels 356 0.5× 439 0.9× 87 0.3× 209 1.0× 188 1.2× 30 949
Kris F. Sachsenmeier 740 1.1× 664 1.4× 267 0.9× 94 0.4× 110 0.7× 46 1.7k
Benjamin I. Leach 317 0.5× 674 1.4× 87 0.3× 176 0.8× 195 1.3× 29 1.2k
Amy E. McCart Reed 685 1.0× 707 1.5× 97 0.3× 359 1.7× 534 3.4× 66 1.5k
Björn G. Voldborg 251 0.4× 710 1.5× 195 0.7× 138 0.7× 63 0.4× 31 1.0k
Sachi Horibata 477 0.7× 838 1.7× 127 0.5× 123 0.6× 281 1.8× 31 1.6k
Yiyu Dong 328 0.5× 731 1.5× 66 0.2× 220 1.0× 203 1.3× 26 1.2k
Alihossein Saberi 464 0.7× 1.1k 2.4× 94 0.3× 91 0.4× 291 1.9× 62 1.5k

Countries citing papers authored by Denis M. Collins

Since Specialization
Citations

This map shows the geographic impact of Denis M. Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis M. Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis M. Collins more than expected).

Fields of papers citing papers by Denis M. Collins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denis M. Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis M. Collins. The network helps show where Denis M. Collins may publish in the future.

Co-authorship network of co-authors of Denis M. Collins

This figure shows the co-authorship network connecting the top 25 collaborators of Denis M. Collins. A scholar is included among the top collaborators of Denis M. Collins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denis M. Collins. Denis M. Collins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Crown, John, et al.. (2025). Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. International Journal of Molecular Sciences. 26(2). 460–460.
2.
Conlon, Neil T., Sandra Roche, Laura Breen, et al.. (2024). Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo. Translational Oncology. 49. 102073–102073. 2 indexed citations
3.
Jordan, Emmet, et al.. (2024). Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells. Cancer Chemotherapy and Pharmacology. 93(5). 427–437. 4 indexed citations
4.
5.
Blanco, Alfonso, Stephen F. Madden, Barry Moran, et al.. (2023). Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy. British Journal of Cancer. 129(6). 1022–1031. 6 indexed citations
6.
Roche, Sandra, Patricia Gaule, Nupur Mukherjee, et al.. (2023). Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer. PLoS ONE. 18(3). e0282512–e0282512. 6 indexed citations
7.
Conlon, Neil T., Suzanne J.C. van Gerwen, Guido J.R. Zaman, et al.. (2021). Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. British Journal of Cancer. 124(7). 1249–1259. 39 indexed citations
8.
Breen, Laura, Patricia Gaule, Alexandra Canonici, et al.. (2020). Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. Investigational New Drugs. 38(5). 1365–1372. 10 indexed citations
9.
Charmsaz, Sara, Denis M. Collins, Antoinette S. Perry, & Maria Prencipe. (2019). Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference. Cancers. 11(8). 1125–1125. 51 indexed citations
10.
Charmsaz, Sara, Maria Prencipe, Maeve Kiely, Graham P. Pidgeon, & Denis M. Collins. (2018). Innovative Technologies Changing Cancer Treatment. Cancers. 10(6). 208–208. 22 indexed citations
11.
Canonici, Alexandra, Neil T. Conlon, Kasper Pedersen, et al.. (2018). HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Investigational New Drugs. 37(3). 441–451. 21 indexed citations
12.
Canonici, Alexandra, Neil T. Conlon, Denis M. Collins, et al.. (2018). The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Investigational New Drugs. 36(4). 581–589. 19 indexed citations
13.
Collins, Denis M., Kathy Gately, Anthony M. Davies, et al.. (2017). Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. Cellular Immunology. 319. 35–42. 24 indexed citations
14.
Guibourdenche, M, Brigid C. Browne, Lorraine O’Driscoll, et al.. (2017). Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model. Annals of Oncology. 28. v4–v4. 1 indexed citations
15.
Collins, Denis M., Wolfgang Jacob, Juan Miguel Cejalvo, et al.. (2017). Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. PLoS ONE. 12(5). e0177331–e0177331. 39 indexed citations
16.
Sousa, Paul A. De, K. Bruce, Denis M. Collins, et al.. (2016). Derivation of the clinical grade human embryonic stem cell line RCe018-A (RC-14). Stem Cell Research. 16(3). 761–765. 20 indexed citations
17.
Collins, Denis M., Norma O’Donovan, Patricia M. McGowan, et al.. (2011). Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Annals of Oncology. 23(7). 1788–1795. 114 indexed citations
18.
Tryfonopoulos, Dimitrios, S. Walsh, Denis M. Collins, et al.. (2011). Src: a potential target for the treatment of triple-negative breast cancer. Annals of Oncology. 22(10). 2234–2240. 113 indexed citations
19.
Walsh, Naomi, Susan Kennedy, A. Larkin, et al.. (2010). Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. British Journal of Cancer. 102(7). 1157–1162. 32 indexed citations
20.
Buddle, Bryce M. & Denis M. Collins. (2008). Development of tuberculosis vaccines for cattle.. CABI Reviews. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James Russell Breakdown of academic impact, for papers by Antje‐Christine Walz Breakdown of academic impact, for papers by Bea Pauwels Breakdown of academic impact, for papers by Kris F. Sachsenmeier Breakdown of academic impact, for papers by Benjamin I. Leach Breakdown of academic impact, for papers by Amy E. McCart Reed Breakdown of academic impact, for papers by Björn G. Voldborg Breakdown of academic impact, for papers by Sachi Horibata Breakdown of academic impact, for papers by Yiyu Dong Breakdown of academic impact, for papers by Alihossein Saberi
Rankless by CCL
2026